A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/01/2011	US20110293643 Compounds and methods for inhibiting mmp2 and mmp9
12/01/2011	US20110293640 Cholinesterase Inhibitors for Treating Inflammation
12/01/2011	US20110293639 Ideotypically modulated pharmacoeffectors for selective cell treatment
12/01/2011	US20110293636 Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf
12/01/2011	US20110293635 Composition and methods for modulating toll-like receptor activity
12/01/2011	US20110293628 Pain treatment using erk2 inhibitors
12/01/2011	US20110293625 Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa
12/01/2011	US20110293624 Genes of an Otitis Media Isolate of NonTypeable Haemophilus Influenzae
12/01/2011	US20110293615 Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor
12/01/2011	US20110293610 Antibodies that immunospecifically bind to b lymphocyte stimulator protein
12/01/2011	US20110293607 Antibody Variants Having Modifications In The Constant Region
12/01/2011	US20110293600 Anticancer Composition Comprising Antitumor Agent and Substance Having Inhibitory Effects on L1CAM Activity and Expression
12/01/2011	US20110293599 Method for modulating muscle differentiation or regeneration
12/01/2011	US20110293595 Prophylactic and therapeutic treatment of Alzheimer's Disease, neuro-degenerative diseases, protein aggregation diseases, Parkinson's Disease and amyloid diseases, using phytic acid and phytate
12/01/2011	US20110293592 Method of treating coronary arteries with perivascular delivery of therapeutic agents
12/01/2011	US20110293589 Method of treating vitamin b12 deficiency
12/01/2011	US20110293588 Metabolic uncoupling therapy
12/01/2011	US20110293587 Glucagon analogues
12/01/2011	US20110293586 Glucagon analogues
12/01/2011	US20110293582 Methods for enhancing hematopoietic stem/progenitor cell engraftment
12/01/2011	US20110293575 Photochemical internalisation of kinase inhibitors
12/01/2011	US20110293564 2-morpholino-pyrido[3,2-d]pyrimidines
12/01/2011	US20110293563 1'substituted carba-nucleoside analogs for antiviral treatment
12/01/2011	US20110293562 Use of cardiotrophin-1 for the treatment of metabolic diseases
12/01/2011	US20110293558 Material properties of t cells and related methods and compositions
12/01/2011	US20110293556 Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia
12/01/2011	US20110293549 Composition, method and kit for enhancing hair
12/01/2011	US20110293537 formulations with anti-neoplastic activity
12/01/2011	US20110293536 Buccal, polar and non-polar spray containing zolipidem
12/01/2011	US20110293534 Aerosol can spray incorporating a nutritional cell scaffold for use as first aid treatment for wounds/burns and for use in cell therapy/tissue repair
12/01/2011	US20110293531 Porphyrazine Optical and Dual Optical/MR Contrast and Therapeutic Agents
12/01/2011	US20110293528 Enema preparations and their use
12/01/2011	US20110293526 Compositions and methods to modulate hair growth
12/01/2011	US20110293524 Methods and compositions for the regulation of lectin complement pathway (lcp)-associated complement activation in hyperglycemic myocardial damage
12/01/2011	US20110293522 Surface modification of polymers via surface active and reactive end groups
12/01/2011	US20110293521 Anti-viral compositions and methods for administration
12/01/2011	US20110293520 New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
12/01/2011	US20110290693 Abnormal Scar Therapy
12/01/2011	DE102010029399A1 Cyclische Dipeptide als Futtermitteladditive Cyclic dipeptides as feed additives
12/01/2011	DE102010022587A1 Gastric juice-resistant composition for oral ingestion of plant-based components, useful for preventing colorectal cancer, comprises glucosinolate, and a construct of glucan-melanin-chitin complex coated with plant-based component
12/01/2011	DE102010021671A1 Azelainsäurehaltige Formulierung mit Pigmentzusatz Azelainsäurehaltige formulation with added pigment
12/01/2011	DE102010021637A1 Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung Substituted 5-fluoro-1H-pyrazolopyridines, and their use
12/01/2011	DE102010017130A1 Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung Hybrid compound, use thereof and process for their preparation
12/01/2011	CA2837129A1 2-iminobiotin formulations and uses thereof
12/01/2011	CA2836175A1 Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
12/01/2011	CA2819383A1 Compositions and methods for treating bruises
12/01/2011	CA2806619A1 Anti-diabetic compositions and methods
12/01/2011	CA2804304A1 Heterocyclic compounds and uses thereof
12/01/2011	CA2801020A1 A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
12/01/2011	CA2800958A1 Macrocyclic compounds useful as inhibitors of histone deacetylases
12/01/2011	CA2800910A1 Pharmaceutical dosage form containing an antipsychotic agent
12/01/2011	CA2800838A1 Combination therapy for skin disorders
12/01/2011	CA2800811A1 Oligo-benzamide compounds and their use
12/01/2011	CA2800743A1 Apple skin extracts for treating cardiovascular disease
12/01/2011	CA2800724A1 Novel indazole derivative or salt thereof and production intermediate thereof, and antioxidant using same, and use of indazole derivative or salt thereof
12/01/2011	CA2800716A1 Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith
12/01/2011	CA2800709A1 The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc)
12/01/2011	CA2800697A1 Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
12/01/2011	CA2800618A1 Heteroaryl compounds and methods of use thereof
12/01/2011	CA2800589A1 Compositions comprising botanicals, including the use and method of use thereof
12/01/2011	CA2800541A1 Soluble guanylate cyclase activators
12/01/2011	CA2800530A1 Inhibitors of hcv ns5a
12/01/2011	CA2800521A1 Fused imidazole derivative
12/01/2011	CA2800509A1 Inhibitors of hcv ns5a
12/01/2011	CA2800412A1 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
12/01/2011	CA2800384A1 Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
12/01/2011	CA2800383A1 Tamarind seed polysaccharide for use in the treatment of inflammatory diseases
12/01/2011	CA2800382A1 Tamarind seed polysaccharide for use in the treatment of microbial infections
12/01/2011	CA2800251A1 Compositions and methods for reduction of mercury toxicity
12/01/2011	CA2800176A1 Bicyclic heteroaryl kinase inhibitors and methods of use
12/01/2011	CA2800167A1 Methods for increasing the production or activity of catalase
12/01/2011	CA2800103A1 Pyrazole compounds as sigma receptor inhibitors
12/01/2011	CA2800021A1 Levoisovalerylspiramycin i, ii, iii and preparations, preparation methods and uses thereof
12/01/2011	CA2800019A1 Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof
12/01/2011	CA2799966A1 Substituted-6-methylnicotinamides as mglur5 positive allosteric modulators
12/01/2011	CA2799926A1 Heterocyclic compounds as janus kinase inhibitors
12/01/2011	CA2799771A1 Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
12/01/2011	CA2799596A1 Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
12/01/2011	CA2799591A1 Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
12/01/2011	CA2799280A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
12/01/2011	CA2799207A1 Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
12/01/2011	CA2799203A1 Nicotinic receptor non-competitive antagonists
12/01/2011	CA2799136A1 Vaccine against streptococcal infections based on recombinant proteins
12/01/2011	CA2799029A1 Process for the preparation of pleuromutilins
12/01/2011	CA2799007A1 Oral pharmaceutical composition of duloxetine
12/01/2011	CA2798811A1 Topical pharmaceutical or cosmetic composition useful for the treatment of diseases or conditions that transcur through a deficit of maturation of the cornified envelope
12/01/2011	CA2798765A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
12/01/2011	CA2798419A1 8-hydroxy-quinoline derivatives
12/01/2011	CA2794868A1 Effervescent composition for forming a gelled composition, tablet for forming a gelled composition, and method of making a gelled composition
12/01/2011	CA2794553A1 Topical pharmaceutical compositions comprising mometasone furoate
12/01/2011	CA2794420A1 Injectable emulsion of sedative hypnotic agent
12/01/2011	CA2791806A1 Nutritional compositions
11/2011
11/30/2011	EP2390327A1 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
11/30/2011	EP2390260A2 Ester derivative of ethinyl estradiol
11/30/2011	EP2390257A1 2'-fluoronucleosides
11/30/2011	EP2390255A1 Novel aminoglycosides and uses thereof in the treatment of genetic disorders
11/30/2011	EP2390254A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND
11/30/2011	EP2390252A1 New pyrazole derivatives
11/30/2011	EP2390251A1 Optical pure quinazoline compounds
11/30/2011	EP2390250A2 Gonadotropin releasing hormone receptor antagonists, manufacturing method thereof, and pharmaceutical composition containing same

1 ... 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 ... 7860